Article Figures & Data
Figures
- Figure 1.
Effects of 72 h treatment with Vitamin D-binding Protein-derived Macrophage-activating Factor (DBP-MAF) on MCF-7 cell proliferation. A: Assessment of cell proliferation by methyl-thiazol-tetrazolium (MTT)-based assay. Treatment columns 1: control (VDBP, 40 ng/ml); 2: DBP-MAF, 0.4 ng/ml.; 3: vitamin D (1,25(OH)-2D-3), 100 nM; 4: DBP-MAF, 40 ng/ml; 5: 1,25(OH)-2D-3, 1 μM; 6: 1,25(OH)-2D-3, 1 μM + DBP-MAF, 40 ng/ml. Values represent means±SEM (n=12). *p<0.05 vs. Control; **p<0.01 vs. control. B: Assessment of cell proliferation by cell counting. MCF-7 cells (2×105 cells per well) were seeded in 24-well plates and cell number after 72 h assessed using a haematocytometer. Treatment columns 1: control; 2: DBP-MAF 0.4 ng/ml. Values represent means±SEM (n=12). **p<0.01 vs. control.
- Figure 2.
Effects of 72 h treatment with Vitamin D-binding Protein-derived Macrophage-activating Factor (DBP-MAF) on MCF-7 cell morphology under phase-contrast light microscopy. MCF-7 cells treated for 72 h with 40 ng/ml Vitamin D-binding Protein (VDBP) (control) (A; arrows indicate cell clusters), 40 ng/ml DBP-MAF (B), 0.4 ng/ml VDBP (C), and with 0.4 ng/ml DBP-MAF (D). Scale bar=50 μm.
- Figure 3.
Effects of 24 h treatment with Vitamin D-binding Protein-derived Macrophage-activating Factor (DBP-MAF) on MCF-7 cell morphology under phase-contrast light microscopy. MCF-7 cells treated for 24 h with 40 ng/ml VDBP Vitamin D-binding Protein (VDBP) (control) (A) and with 40 ng/ml DBP-MAF (B). Scale bar=25 μm.
- Figure 4.
Effects of 72 h treatment with Vitamin D-binding Protein-derived Macrophage-activating Factor (DBP-MAF) on MCF-7 cell morphology after Papanicolaou stain under light microscopy. MCF-7 cells treated for 72 h with 40 ng/ml Vitamin D-binding Protein (VDBP) (control) (A; arrows indicate cell clusters), and with 40 ng/ml DBP-MAF (B). Scale bar=25 μm.
- Figure 5.
Effects of 72 h treatment with Vitamin D-binding Protein-derived Macrophage-activating Factor (DBP-MAF) on vimentin expression in MCF-7 cells. Immunohistochemistry of MCF-7 cells treated for 72 h with 40 ng/ml Vitamin D-binding Protein (VDBP) (control) (A) and with 40 ng/ml DBP-MAF (B). Scale bar=25 μm. Densitometric analysis of vimentin expression determined by immunohistochemistry (C). Brown stained areas of panels A (column 1, control), and B (column 2, DBP-MAF) were measured by Scion Image software and expressed as square pixels. Western blot analysis and densitometric evaluation of vimentin expression (D). Band 1 and column 1 (densitometric analysis of the actual band) refer to MCF-7 cells treated for 72 h with 40 ng/ml VDBP. Band 2 and column 2 refer to MCF-7 cells treated for 72 h with 40 ng/ml DBP-MAF. Areas of bands 1 (control), and 2 (DBP-MAF) were measured by Scion Image software and expressed as square pixels. Values in densitometric analyses indicate means±SEM (n=3). *p<0.01 vs. control. B-Actin signal was used for reference.
Tables
In this issue
Jump to section
Related Articles
Cited By...
- Prediagnostic Circulating Concentrations of Vitamin D Binding Protein and Survival among Patients with Colorectal Cancer
- Vitamin D-Binding Protein and Risk of Renal Cell Carcinoma in the Cancer Prevention Study-II Cohort
- Weight Status and Alcohol Intake Modify the Association between Vitamin D and Breast Cancer Risk
- Case Report: A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy
- Oleic Acid, Deglycosylated Vitamin D-Binding Protein, Nitric Oxide: A Molecular Triad Made Lethal to Cancer
- Clinical Experience of Integrative Cancer Immunotherapy with GcMAF
- Circulating DBP level and prognosis in operated lung cancer: an exploration of pathophysiology